New drug PHN-012 targets Hard-to-Treat cancers in first human trial
Disease control
Recruiting now
This early-stage study tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancers that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The m…
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:00 UTC